Ras/MAPK signalling intensity defines subclonal fitness in a mouse model of hepatocellular carcinoma

  1. Anthony Lozano
  2. Francois-Régis Souche
  3. Carine Chavey
  4. Valérie Dardalhon
  5. Christel Ramirez
  6. Serena Vegna
  7. Guillaume Desandre
  8. Anaïs Riviere
  9. Amal Zine El Aabidine
  10. Philippe Fort
  11. Leila Akkari
  12. Urszula Hibner  Is a corresponding author
  13. Damien Grégoire  Is a corresponding author
  1. University of Montpellier, CNRS, France
  2. Oncode Institute, Netherlands
  3. French National Centre for Scientific Research, France

Abstract

Quantitative differences in signal transduction are to date an understudied feature of tumour heterogeneity. The MAPK Erk pathway, which is activated in a large proportion of human tumours, is a prototypic example of distinct cell fates being driven by signal intensity. We have used primary hepatocyte precursors transformed with different dosages of an oncogenic form of Ras to model subclonal variations in MAPK signalling. Orthotopic allografts of Ras-transformed cells in immunocompromised mice gave rise to fast-growing aggressive tumours, both at the primary location and in the peritoneal cavity. Fluorescent labelling of cells expressing different oncogene levels, and consequently varying levels of MAPK Erk activation, highlighted the selection processes operating at the two sites of tumour growth. Indeed, significantly higher Ras expression was observed in primary as compared to secondary, metastatic sites, despite the apparent evolutionary trade-off of increased apoptotic death in the liver that correlated with high Ras dosage. Analysis of the immune tumour microenvironment at the two locations suggests that fast peritoneal tumour growth in the immunocompromised setting is abrogated in immunocompetent animals due to efficient antigen presentation by peritoneal dendritic cells. Furthermore, our data indicate that, in contrast to the metastatic-like outgrowth, strong MAPK signalling is required in the primary liver tumours to resist elimination by NK cells. Overall, this study describes a quantitative aspect of tumour heterogeneity and points to a potential vulnerability of a subtype of hepatocellular carcinoma as a function of MAPK Erk signalling intensity.

Data availability

The RNA-sequencing data have been deposited in the Gene Expression Omnibus (GEO, NCBI) repository, and are accessible through GEO Series accession number GSE180580. Raw data from figures 1 to 5 were deposited on Mendeley data at doi: 10.17632/73nbvs8925.1.

The following data sets were generated

Article and author information

Author details

  1. Anthony Lozano

    Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Francois-Régis Souche

    Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Carine Chavey

    Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Valérie Dardalhon

    Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Christel Ramirez

    Division of Tumor Biology and Immunology, Oncode Institute, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  6. Serena Vegna

    Division of Tumor Biology and Immunology, Oncode Institute, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  7. Guillaume Desandre

    Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Anaïs Riviere

    Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Amal Zine El Aabidine

    Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Philippe Fort

    Centre de Recherche en Biologie Cellulaire de Montpellier, French National Centre for Scientific Research, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5997-8722
  11. Leila Akkari

    Division of Tumor Biology and Immunology, Oncode Institute, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  12. Urszula Hibner

    Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
    For correspondence
    ula.hibner@igmm.cnrs.fr
    Competing interests
    The authors declare that no competing interests exist.
  13. Damien Grégoire

    Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
    For correspondence
    damien.gregoire@igmm.cnrs.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1105-8115

Funding

SIRIC Montpellier Cancer (Grant INCa_Inserm_DGOS_12553)

  • Urszula Hibner

Grant HTE-ITMO Cancer (HTE201610)

  • Urszula Hibner

Association Francaise pour l'Etude du Foie

  • Damien Grégoire

Dutch Cancer Society (KWF 12049/2018-2)

  • Leila Akkari

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All reported animal procedures were carried out in accordance with the rules of the FrenchInstitutional Animal Care and Use Committee and European Community Council(2010/63/EU). Animal studies were approved by institutional ethical committee (Comitéd'éthique en expérimentation animale Languedoc-Roussillon (#36)) and by the Ministère del'Enseignement Supérieur, de la Recherche et de l'Innovation (APAFIS#11196-2018090515538313v2).

Reviewing Editor

  1. Roger J Davis, University of Massachusetts Medical School, United States

Publication history

  1. Received: December 13, 2021
  2. Accepted: January 18, 2023
  3. Accepted Manuscript published: January 19, 2023 (version 1)

Copyright

© 2023, Lozano et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 136
    Page views
  • 37
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Anthony Lozano
  2. Francois-Régis Souche
  3. Carine Chavey
  4. Valérie Dardalhon
  5. Christel Ramirez
  6. Serena Vegna
  7. Guillaume Desandre
  8. Anaïs Riviere
  9. Amal Zine El Aabidine
  10. Philippe Fort
  11. Leila Akkari
  12. Urszula Hibner
  13. Damien Grégoire
(2023)
Ras/MAPK signalling intensity defines subclonal fitness in a mouse model of hepatocellular carcinoma
eLife 12:e76294.
https://doi.org/10.7554/eLife.76294

Further reading

    1. Cancer Biology
    2. Microbiology and Infectious Disease
    Changkun Hu, Taylor Bugbee ... Nicholas Wallace
    Research Article

    Double strand breaks (DSBs) are one of the most lethal DNA lesions in cells. The E6 protein of beta-human papillomavirus (HPV8 E6) impairs two critical DSB repair pathways; homologous recombination (HR) and non-homologous end-joining (NHEJ). However, HPV8 E6 only delays DSB repair. How DSBs are repaired in cells with HPV8 E6 remains to be studied. We hypothesize that HPV8 E6 promotes a less commonly used DSB repair pathway, alternative end-joining (Alt-EJ). Using CAS9 based Alt-EJ reporters, we show that HPV8 E6 promotes Alt-EJ. Further, using small molecule inhibitors, CRISPR/CAS9 gene knockout, and HPV8 E6 mutant, we find that HPV8 E6 promotes Alt-EJ by binding p300, an acetyltransferase that facilitates DSB repair by HR and NHEJ. At least some of this repair occurs through a subset of Alt-EJ known as polymerase theta dependent end joining. Finally, whole genome sequencing analysis showed HPV8 E6 caused an increased frequency of deletions bearing the microhomology signatures of Alt-EJ. This study fills the knowledge gap of how DSB is repaired in cells with HPV8 E6 and the mutagenic consequences of HPV8 E6 mediated p300 destabilization. Broadly, this study supports the hypothesis that beta-HPV promotes cancer formation by increasing genomic instability.

    1. Cancer Biology
    2. Cell Biology
    Kimberly J Morgan, Karen Doggett ... Joan Kathleen Heath
    Research Article

    The nucleoporin (NUP) ELYS, encoded by AHCTF1, is a large multifunctional protein with essential roles in nuclear pore assembly and mitosis. Using both larval and adult zebrafish models of hepatocellular carcinoma (HCC), in which the expression of an inducible mutant kras transgene (krasG12V) drives hepatocyte-specific hyperplasia and liver enlargement, we show that reducing ahctf1 gene dosage by 50% markedly decreases liver volume, while non-hyperplastic tissues are unaffected. We demonstrate that in the context of cancer, ahctf1 heterozygosity impairs nuclear pore formation, mitotic spindle assembly and chromosome segregation, leading to DNA damage and activation of a Tp53-dependent transcriptional program that induces cell death and cell cycle arrest. Heterozygous expression of both ahctf1 and ranbp2 (encoding a second nucleoporin), or treatment of heterozygous ahctf1 larvae with the nucleocytoplasmic transport inhibitor, Selinexor, completely blocks krasG12V-driven hepatocyte hyperplasia. Gene expression analysis of patient samples in the Liver hepatocellular carcinoma (LIHC) dataset in The Cancer Genome Atlas shows that high expression of one or more of the transcripts encoding the ten components of the NUP107-160 sub-complex, which includes AHCTF1, is positively correlated with worse overall survival. These results provide a strong and feasible rationale for the development of novel cancer therapeutics that target ELYS function and suggest potential avenues for effective combinatorial treatments.